- Home
- STRO vs BAFN Comparison
STRO vs BAFN Comparison
Compare STRO & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- BAFN
- Stock Information
- Founded
- STRO 2003
- BAFN 1999
- Country
- STRO United States
- BAFN United States
- Employees
- STRO N/A
- BAFN N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- BAFN Savings Institutions
- Sector
- STRO Health Care
- BAFN Finance
- Exchange
- STRO Nasdaq
- BAFN Nasdaq
- Market Cap
- STRO 77.7M
- BAFN 65.2M
- IPO Year
- STRO 2018
- BAFN N/A
- Fundamental
- Price
- STRO $0.90
- BAFN $15.12
- Analyst Decision
- STRO Hold
- BAFN
- Analyst Count
- STRO 7
- BAFN 0
- Target Price
- STRO $5.47
- BAFN N/A
- AVG Volume (30 Days)
- STRO 1.2M
- BAFN 6.6K
- Earning Date
- STRO 05-08-2025
- BAFN 07-24-2025
- Dividend Yield
- STRO N/A
- BAFN 2.03%
- EPS Growth
- STRO N/A
- BAFN 113.18
- EPS
- STRO N/A
- BAFN 2.34
- Revenue
- STRO $66,434,000.00
- BAFN $80,167,000.00
- Revenue This Year
- STRO N/A
- BAFN N/A
- Revenue Next Year
- STRO N/A
- BAFN N/A
- P/E Ratio
- STRO N/A
- BAFN $6.97
- Revenue Growth
- STRO N/A
- BAFN 2.60
- 52 Week Low
- STRO $0.52
- BAFN $11.00
- 52 Week High
- STRO $5.17
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- STRO 50.82
- BAFN 47.25
- Support Level
- STRO $0.86
- BAFN $14.79
- Resistance Level
- STRO $0.99
- BAFN $16.35
- Average True Range (ATR)
- STRO 0.09
- BAFN 0.45
- MACD
- STRO 0.00
- BAFN 0.07
- Stochastic Oscillator
- STRO 68.44
- BAFN 33.51
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.